Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Revision Reduces Expected CDER Staffing Increases By 139 FTEs

Executive Summary

A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.

You may also be interested in...



FDA To Discuss "PDUFA III" Agenda At September Meeting

FDA is soliciting public input into its goals for reauthorization of the Prescription Drug User Fee Act.

FDA To Discuss "PDUFA III" Agenda At September Meeting

FDA is soliciting public input into its goals for reauthorization of the Prescription Drug User Fee Act.

FDA Wants More "Predictable" Revenue Stream Under PDUFA III

FDA would like to ensure a more "predictable" revenue stream under the third Prescription Drug User Fee Act.

Related Content

UsernamePublicRestriction

Register

PS034765

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel